Podcasts, Videos and Webinars

Non-Small Cell Lung Cancer Immunotherapy: A New HopeTM

Non-small Cell Lung Cancer Immunotherapy: A New Hope is an animated video that follows a patient’s journey from her diagnosis of NSCLC through the process of learning about cancer immunology, leading to her consideration of cancer immunotherapy treatments via clinical trial participation.

This video was created by the Society for Immunotherapy of Cancer (SITC), in partnership with LUNGevity Foundation, the Association of Community Cancer Centers, the Bonnie J. Addario Lung Cancer Foundation, Cancer Support Community, and the Lung Cancer Alliance.

Webinar Library

Lung Cancer Highlights 2012, Dr. Natasha Leighl, Princess Margaret Hospital and University of Toronto

Small Cell Lung Cancer, Dr. Antoinette Wozniak, Karmanos Cancer Center at Wayne State University

Refining Prognosis of Early Stage Lung Cancer by Molecular Features, Dr. Johannes Kratz, Massachusetts General Hospital

Advances in Surgery for Lung Cancer, Dr. David Harpole, Duke University Medical Center

Practical Aspects of Clinical Trials in Cancer: Myths and Facts, Dr. Suresh Ramalingam, Winship Cancer Center at Emory University

Molecular Pathology in Lung Cancer, Dr. Dara Aisner, Colorado Molecular Correlates Laboratory and University of Colorado

New Radiation Techniques for Lung Cancer, Dr. Vivek Mehta, Swedish Cancer Institute

ASCO Conference 2012 Review, Dr. Joel Neal, Stanford University, and Dr. Mark Socinski, University of Pittsburgh

Managing Pulmonary Complications in Lung Cancer, Dr. Gerard Silvestri, Medical University of South Carolina

Symptom Management and Palliative Care in People with Lung Cancer, Dr. Stephanie Harman, Stanford University

Immunotherapies for Lung Cancer: Can We Deliver on the Promise?  Dr. Ramaswamy Govindan, Washington University,  and Dr. Julie Brahmer, Sidney Kimmel Cancer Center at Johns Hopkins University

Molecular Markers in Advanced NSCLC: Who to Test and What to Test For, Dr. Alice Shaw, Massachusetts General Hospital; Dr. Charlie Rudin, Johns Hopkins University; Dr. David Spigel, Sarah Cannon Cancer Center; and Dr. Glen Goss, University of Ottawa

2011 Highlights in Lung Cancer, Dr. Jared Weiss, Lineberger Cancer Center at the University of North Carolina at Chapel Hill

Smoking Trends and Practical Cessation Strategies, Dr. Mark W. Willard, Baylor Martha Foster Lung Care Center and Baylor University Medical Center

Evaluation & Management of Pulmonary Nodules, Dr. David Yankelevitz, Mount Sinai Medical Center

ALK Inhibition: From Biology to Approved Therapy, Dr. D. Ross Camidge, University of Colorado Denver, and Dr. Ben Solomon, Peter MacCallum Cancer Centre

Special Considerations in Treating Elderly Patients with Lung Cancer, Dr. Rogerio Lilenbaum, Cleveland Clinic Foundation

Dermatologic side effects of anti-cancer therapies, Dr. Mario Lacouture, Memorial Sloan-Kettering Cancer Center

Post-ASCO Highlights in Lung Cancer Research, Dr. Mary Pinder,  H. Lee Moffitt Cancer Center, and Dr. Nasser Hanna, Indiana University Cancer Center

Radiation for Prevention and Management of Brain Metastases in Lung Cancer, Dr. Minesh Mehta, Northwestern University

Acquired Resistance to EGFR Inhibitors, Dr. Lecia Sequist, Harvard Medical School and Massachusetts General Hospital

Challenging Cases in Lung Cancer Series, Dr. Jack West and various panelists

Video Library

Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients? Dr. Nasser Hanna, Indiana University, and Dr. Melissa Johnson, Northwestern University
Is Progression-Free Survival Meaningful? Dr. Nasser Hanna, Indiana University, and Dr. Melissa Johnson, Northwestern University
Does Gilotrif Help EGFR Positive Lung Cancer Patients? Dr. Nasser Hanna, Indiana University, and Dr. Melissa Johnson, Northwestern University
 Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? Dr. Nasser Hanna, Indiana University, and Dr. Melissa Johnson, Northwestern University
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer? Dr. Nasser Hanna, Indiana University
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation? Dr. Nasser Hanna, Indiana University, and Dr. Melissa Johnson, Northwestern University

Targeted Therapies in Lung Cancer Conference: The My Cancer Genome Project, Dr. William Pao, Vanderbilt University

What is an inherited EGFR T790M mutation, and what does it mean? Dr. Geoffrey Oxnard, Dana Farber Cancer Institute

Molecular marker testing in advanced NSCLC:  what, who, and when? Dr. Lecia Sequist, Massachusetts General Hospital

What are the most promising targeted therapies for lung cancer in the next few years? Dr. David Spigel, Sarah Cannon Cancer Center

How should we approach acquired resistance to targeted therapies in advanced NSCLC? Dr. Greg Riely, Memorial Sloan-Kettering Cancer Center

How should we use molecular marker information in earlier stage NSCLC? Dr. Heather Wakelee, Stanford University

What molecular markers do you routinely send for in your patients with advanced NSCLC? Dr. Karen Kelly, University of California, Davis

How do you discuss the pros and cons of molecular testing, with potential delays and need for rebiopsy? Dr. Sarah Goldberg, Yale School of Medicine

Who do you recommend repeat biopsy for if there isn't enough tissue for molecular testing? Dr. Ross Camidge, University of Colorado, and Dr. Corey Langer, University of Pennsylvania

Will we be able to use molecular markers and apply targeted therapies to broader lung cancer subtypes in the near future? Dr. Bob Doebele, University of Colorado

How should we approach acquired resistance to targeted therapies in advanced NSCLC? Dr. Greg Riely, Memorial Sloan-Kettering Cancer Center

Management strategies for acquired resistance to targeted therapies, single focus or more diffuse? Dr. Ravi Salgia, University of Chicago

Managing acquired resistance to EGFR inhibitor therapy (and probably crizotinib, too), Dr. Geoffrey Oxnard, Dana Farber Cancer Institute

What Are the Most Promising Novel Agents Coming on the Lung Cancer Scene? Several Experts Weigh In

My approach to maintenance therapy for advanced NSCLC, Dr. Ravi Salgia, University of Chicago

Options for maintenance therapy: switch, continuation, or a treatment break? Dr. Alan Sandler, Oregon Health

The potential value of a treatment break as an alternative to maintenance therapy in advanced NSCLC, Dr. Sarah Goldberg, Yale School of Medicine

Is maintenance therapy after first-line chemotherapy a mandate, an option, or neither? Dr. Phil Bonomi, Rush University

What are the most promising emerging treatments for lung cancer for the next few years? Various experts

How do you approach the question of repeat biopsies for lung cancer?  Various experts

ASCO Highlights in Lung Cancer Research: Key findings from the PROSE trial

ASCO Highlights in Lung Cancer Research: Key findings from the MADeIT trial
ASCO Highlights in Lung Cancer Research: "Biomarkers France"
 
 

 

 

 


Lung Cancer Highlights 2012

Dr. Natasha LeighlWe end our monthly live webinar series, co-sponsored by GRACE along with LUNGevity Foundation, with our annual "Highlights in Lung Cancer" program. This one, featuring the leading developments from 2012, was be by Dr. Natasha Leighl, medical oncologist and lung cancer expert at Princess Margaret Hospital, as well as Assistant Professor of Medicine at the University of Toronto in Ontario, Canada.

She covered topics ranging from immunotherapy to new targets and potential targeted therapies, as well as newly identified mechanisms of acquired resistance and potential strategies for addressing this.

Her presentation opened with new information on potential treatment options for patients with  advanced NSCLC that has an EGFR mutation.

Video Podcast     Audio Podcast    Illustrations  (pdf)

She continued her tour of  lung cancer highlights with a discussion on XALKORI (crizotinib) for patients with either an ALK rearrangement or the newly identified ROS-1 rearrangement.

Video Podcast     Audio Podcast    Illustrations  (pdf)

Part 3 focused on exciting research presented at ASCO 2012 and recently published on the promising evidence of efficacy of selumetinib, one of a new class of targeted agents called MEK inhibitors, for the 20-25% of patients who have a KRAS mutation.

Video Podcast     Audio Podcast    Illustrations  (pdf)

Dr. Leighl continued with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a “driver mutation” like an EGFR mutation or an ALK rearrangement.

Video Podcast     Audio Podcast    Illustrations  (pdf)

Small Cell Lung Cancer

Dr. Antoinette WozniakOur webinar featured Dr. Antoinette (Toni) Wozniak, medical oncologist and Professor of Medicine at Karmanos Cancer Center at Wayne State University in Detroit, MI.  She covered the background of the initial presentation, evaluation, and then the key elements of our current understanding of the best treatment for lung cancer. Finally, she discussed some ongoing questions and potential new treatments in this setting.

While SCLC was the source of much of the excitement in the field of lung cancer 15 years ago, the focus in the last few years has been overwhelmingly on non-small cell lung cancer. But SCLC still accounts for about 12-15% of lung cancer and over 20,000 cases in the US alone.  It’s a big enough area in the field of lung cancer that it’s fitting that it be covered properly in our series of presentations on the field of lung cancer.

Video Podcast    Audio Podcast

Refining Prognosis of Early Stage Lung Cancer by Molecular Features

Dr. Johannes KratzDr. Johannes Kratz, surgeon at Massachusetts General Hospital in Boston, discussed the timely subject of using molecular features of a resected non-small cell lung cancer in order to better understand the probability of the cancer recurring. Could these molecular features improve upon current staging efforts to help us refine our recommendations of which patients should receive post-operative chemotherapy in order to reduce the chance of recurrence?

 

Advances in Surgery for Lung Cancer

Dr. David HarpoleDr. David Harpole, Thoracic Surgeon and Professor of Surgery at Duke University Medical Center in Durham, NC, is among the most highly regarded thoracic surgeons in the country, for his leadership and collaboration in bridging the gaps between thoracic surgeons and other cancer care specialties, for his technical abilities in lung surgery at a renowned surgical center, and for his forward thinking in advancing the science of better understanding the biology of lung cancer to lead us to better care for lung cancer patients.

He joined us for a discussion of timely topics in the field, from defining best standards of lung surgery, to the evidence on minimally invasive lung surgery, to the potential utility of sub-lobectomies for smaller lung cancers, to the use of biological markers to help us better refine our recommendations for additional therapy.

The first part of his presentation focuses on advances in lung cancer staging that been shaped by and also in turn shape lung cancer surgery.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Part 2 discusses techniques ranging from video-assisted thoracic surgery to robotic surgery to sub-lobar resections and other developments offering new promising alternatives.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Practical Aspects of Clinical Trials in Cancer: Myths and Facts

Dr. Suresh RamalingamDr. Suresh Ramalingam, Professor and Medical Oncologist at the Winship Cancer Center at Emory University in Atlanta, GA, and the Chair of the Lung Cancer Committee for the Eastern Cooperative Oncology Group (ECOG), has been leading important trials in lung cancer for well over a decade now and is deeply committed to improving outcomes for patients. As Chair of ECOG's Lung Cancer Committee, he also needs to ensure that the most important, timely trials are being conducted, that they are appealing to patients, caregivers, and treating physicians alike, that they are practically feasible, and that they ensure the best care to participants.

Part 1 covers an intorduction to clinical trials

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Part 2 of his presentation reviewed how we develop everything from the basic premise of what the trial will test, how we develop the statistical tests, trial documentation, and the regulatory requirements leading to a clinical trial becoming available for patient enrollment at an institution.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Part 3 discusses several persistent myths around clinical research in cancer, countered with the real facts, and then included a highlighting of patient rights in clinical trials.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

The program closed with a question and answer session covering emerging challenges of doing trials in a new era of molecular oncology.

Audio Podcast     Transcript (pdf)  

Dr. Dara Aisner on Molecular Pathology in Lung Cancer

Dr. Dara AisnerCovering a topic that is more and more important every week, we'll be featuring Dr. Dara Aisner, Co-Director of the Colorado Molecular Correlates Laboratory and Assistant Professor at the University of Colorado Department of Pathology.  She's the one actually running all of the studies ranging from EGFR to KRAS to ALK and ROS1, and participating in the cutting edge research on future targets.

She talked about the process from biopsy to test results, the barriers and ways to overcome them, and what we can expect molecular oncology to look like in the coming years.

Part 1 covers basic concepts of what a pathologist does and what the new field of molecular pathology actually entails.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Part 2 covers the practical challenges of molecular testing on certain tissues, where to obtain biopsies from, and other current issues that we encounter in real clinical management as we struggle to make molecular testing more routine.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Part 3: Dr. Aisner’s Glimpse into the Future of Molecular Marker Testing

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

New Radiation Techniques for Lung Cancer

Dr. Vivek MehtaOur webinar program featured GRACE Vice President Dr. Vivek Mehta, who is a radiation oncologist and Director of the Center for Advanced Targeted Radiotherapy at Swedish Cancer Institute in Seattle, WA.  He covered several timely topics, ranging from stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer, integration of new radiation technologies for locally advanced lung cancer, potentially curative focal radiation for "oligometastatic" lung cancer, and the challenging option of reirradiation within a previously radiated field.

Part 1 covers the history of history of radiation therapy and the key strategies for improving outcomes with radiation.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

The second part reviews the rationale for the new approach of stereotactic body radiation therapy (SBRT) for early stage lung cancers in patients who are unable or unwilling to undergo surgery to resect their cancer.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

ASCO Conference 2012 Review

ASCOOur annual program on the highlights in lung cancer from the annual ASCO conference, produced by GRACE in partnership with the LUNGevity Foundation, featuring Dr. Joel Neal, Assistant Professor from Stanford University, and Dr. Mark Socinski, Professor and Co-Leader of the Lung Cancer Center of Excellence at the University of Pittsburgh. The topics included a summary of the results and implications from the newest and most important new studies being presented at ASCO, the largest oncology meeting of the year.

Dr. Socinski on the PARAMOUNT trial of maintenance Alimta (pemetrexed):

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Dr. Socinski on Optimal chemo for marginal performance status patients with advanced NSCLC:

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Dr. Socinski on the TAILOR trial of Taxotere (docetaxel) vs. Tarceva (erlotinib) for EGFR mutation-negative advanced NSCLC:

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf) 

Dr. Socinski with an update on critical small cell lung cancer trials from ASCO 2012:

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Dr. Neal on Anti-PD1 Immunotherapy for Advanced NSCLC:

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Dr. Neal on Anti-MEK agent selumetinib for KRAS mutation-positive advanced NSCLC:

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Dr. Neal on the LUX-Lung 3 trial of afatinib vs. chemo as first line therapy for advanced EGFR mutation-positive NSCLC:

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Managing Pulmonary Complications in Lung Cancer

Dr. Gerard SilvestriIn our next webinar presentation from the series co-sponsored by GRACE and LUNGevity Foundation, Dr. Gerard Silvestri, Professor in Pulmonary and Critical Care Medicine at the Medical University of South Carolina (MUSC), covered management issues for common complications in lung cancer.  He addressed issues like pleural effusions, obstruction of a bronchus (airway to a part of the lung), coughing up blood, etc.

The first half of his presentation covers chemotherapy-induced pneumonitis.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

The second half of his presentation briefly covered pulmonary complications of targeted therapies for lung cancer, followed by a good discussion of the common problem of radiation pneumonitis and how it is typically managed.

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations  (pdf)

Symptom Management and Palliative Care in People with Lung Cancer

Dr. Stephanie HarmanDr. Stephanie Harman is the Director of the Palliative Care Program at Stanford University in Palo Alto, CA who led a recent webinar co-sponsored by LUNGevity and GRACE.  This began with a brief discussion of the distinctions between palliative care and hospice/end of life care, as well as the growing attention palliative care is now receiving from many professional societies.

This was then followed by her discussion of key elements of pain management, including the main types of pain, main treatment approaches, and myths that can limit correct use of opioid medications.

Part 1: Dr. Harmon on Palliative Care

Video Podcast     Audio Podcast     Transcript (pdf)     Illustrations (pdf)

Part 2: Dr. Harmon on Pain Management

Video Podcast     Audio Podcast     Transcript (pdf)    Illustrations (pdf)   

Immunotherapies for Lung Cancer: Can We Deliver on the Promise?

Dr. Ramiswamy GovindanDr. Julie BrahmerGRACE and LUNGevity Foundation presented a webinar with two leaders in lung cancer speaking about several of the more promising immune-based treatment for lung cancer.  Dr. Jack West moderated a program with Dr. Ramaswamy Govindan from Washington University in St. Louis and Dr. Julie Brahmer from the Sidney Kimmel Cancer Center at Johns Hopkins University in Baltimore, MD.  Together, they covered topics such as the MAGE-A3 vaccine, Stimuvax, Lucanix, Anti-PDL1, talactoferrin, and others. The presentations by our two guest faculty members were followed by a question and answer session.

Part 1: Dr. Ramaswamy Govindan
Audio podcast    Transcript  (pdf)     Illustrations  (pdf)

Part 2: Dr. Julie Brahmer
Audio podcast    Transcript  (pdf)     Illustrations  (pdf)

Molecular Markers in Advanced NSCLC: Who to Test and What to Test For

Dr. Jack WestGRACE and LUNGevity Foundation hosted a live panel discussion from Santa Monica, where the International Association for the Study of Lung Cancer kicked off its12th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting.  Host Dr. Jack West was joined by four great luminaries from different centers of excellence and with different perspectives on the timely issue of molecular testing in advanced non-small cell lung cancer: Dr. Alice Shaw, Massachusetts General Hospital, Boston, MA; Dr. Charlie Rudin, Johns Hopkins University, Baltimore, MD; Dr. David Spigel, Sarah Cannon Cancer Center, Nashville, TN; and Dr. Glen Goss, University of Ottawa, Ottawa, ON.

Part 1: Dr. Charles Rudin on Molecular Markers in Lung Cancer
Audio podcast    Transcript  (pdf)     Illustrations  (pdf)

Part 2: Dr. Alice Shaw on Clinical Factors Associated with Molecular Markers
Audio podcast    Transcript  (pdf)     Illustrations  (pdf)

Part 3: The Merits of Uniform vs. More Selective Testing
Audio podcast
    Transcript  (pdf)     Illustrations  (pdf)

Part 4: The Promise and the Pitfalls of Broadening the Use of Molecular Markers
Audio podcast    Transcript  (pdf)    

Part 5: Dr. David Spigel on Integrating Markers into Clinical Trials
Audio podcast    Transcript  (pdf)     Illustrations  (pdf)

Part 6: Dr. Goss on Implementing Molecular Markers Across Health Care Systems
Audio podcast
    Transcript  (pdf)     Illustrations  (pdf)

Dr. Jared Weiss on 2011 Highlights in Lung Cancer

Dr. Jared WeissGRACE and the LUNGevity Foundation began 2012 with a presentation of the most important developments in the field of lung cancer from 2011 with Dr. Jared Weiss, Associate Professor in the Dept of Medical Oncology at the Lineberger Cancer Center at the University of North Carolina at Chapel Hill. Dr. Weiss is also well known to many as the Director of the Lung Cancer and Head/Neck Cancer sections of GRACE.  

Dr. Weiss covered his view of the key highlights of lung cancer from the last year, leaving some time in the remainder of the hour-long program for a question and answer session with the live webinar audience. 

Part 1:  Audio podcast    Transcript  (pdf)     Illustrations  (pdf)
Part 2:  Audio podcast    Transcript  (pdf)     Illustrations  (pdf)

Dr. Mark Millard on Smoking Trends and Practical Cessation Strategies

Dr. Mark MillardGRACE and the LUNGevity Foundation spoke with Dr. Mark W. Willard, MD, FACP, Medical Director of the Baylor Martha Foster Lung Care Center and attending pulmonary physician at Baylor University Medical Center in Dallas, TX.  Dr. Millard will provided an interesting historical perspective on how smoking patterns have been associated with changes in lung cancer over time, as well as a practical review of a wide range of strategies that can assist current smokers with cessation strategies.

Audio Podcast     Transcript (pdf)   Illustrations (pdf)

Dr. David Yankelevitz on Evaluation & Management of Pulmonary Nodules

Dr. David YankelevitzGRACE and the LUNGevity Foundation kicked off November as Lung Cancer Awareness Month by providing this webinar by Dr. David Yankelevitz, Professor in the Department of Radiology at the Mount Sinai Medical Center in New York, NY.  Dr. Yankelevitz has a tremendous expertise in assessing the characteristics of lung nodules, how to follow and work up lung nodules, and the implications for lung cancer screening.   His approximately 30-40 minute presentation was  followed by a question and answer session with the live webinar audience.

Audio Podcast     Transcript (pdf)   Illustrations (pdf)

ALK Inhibition: From Biology to Approved Therapy, with Drs. D. Ross Camidge and Ben Solomon

GRACE & LUNGevity Foundation presented a webinar reviewing the newly discovered molecular target of ALK rearrangements, the clinical evidence that led to the FDA approval of the ALK inhibitor XALKORI (crizotinib) in patients with ALK-positive non-small cell lung cancer (NSCLC) after it emerged as one of the most exciting developments in the oncology world over the past few years, and how it is changing the way clinical research in cancer care is conducted.

Dr. Ben Solomon spoke first, providing an overview of the (short) history of the EML4-ALK translocation and how crizotinib began to be studied in the first patients.  He then took us on a tour of the highlights of both the efficacy data for this new agent and the side effect profile.

Audio Podcast     Transcript (pdf)   Illustrations (pdf)

Dr. Camidge led us through the second part of the program.  His focus was on the practical implications from here: with a newly approved therapy of XALKORI tied to a rather uncommon molecular marker, who should we be screening for it?  And what are the options for these patients after they develop acquired resistance to XALKORI?

Audio Podcast     Transcript (pdf)   Illustrations (pdf)

Dr. Rogerio Lilenbaum on Special Considerations in Treating Elderly Patients with Lung Cancer

Dr. Rogerio LilenbaumThe median age of a patient newly diagnosed with lung cancer in the US is just over 70, but most clinical trials in lung cancer are with a disproportionately younger and more fit population than we tend to see in the "real world". How should we actually treat patients who are older and may not be as able to tolerate the treatments that are optimal for younger patients?  Should they receive the same treatments or pursue a more customized strategy?

GRACE and the LUNGevity Foundation are very pleased to partner in providing this free webinar by Dr. Rogerio Lilenbaum, Chair of the Department of Hematology/Oncology at the Cleveland Clinic Foundation in Weston, FL and a world-renowned expert in lung cancer in general and management of elderly and "poor risk" patients with lung cancer as a particular specialty. 

Audio podcast     Transcript (pdf)     Illustrations (pdf)

Dermatologic side effects of anti-cancer therapies

Dr. Mario LacoutureDr. Mario Lacouture, a dermatologist now on faculty and running a busy clinic at Memorial Sloan-Kettering Cancer Center, joined us to do a webinar on Healthy Skin for People Living with Lung Cancer: Managing Dermatologic Symptoms and Side Effects.”  It covers prevention and treatment of problems involving skin, hair, and nails in cancer patients.

  Audio Podcast     Transcript (pdf)    Illustrations (pdf)

Post-ASCO Highlights in Lung Cancer Research

LUNGevity Foundation and GRACE bring you a discussion of the highlights in lung cancer research from the American Society for Clinical Oncology (ASCO) Annual Meeting, the largest cancer conference of the year.

Dr. Mary PinderDr. Nasser HannaDr. Mary Pinder from the H. Lee Moffitt Cancer Center in Tampa, FL discussed the most interesting work in early stage and locally advanced non-small cell lung cancer, small cell lung cancer, and other less common thoracic malignancies like mesothelioma.

Dr. Pinder: Audio Podcast    Transcript (pdf)

Then Dr. Nasser Hanna from Indiana University Cancer Center discussed the new work on advanced/metastatic non-small cell lung cancer. A Q&A session follows.

Dr. Hanna: Audio Podcast   Transcript (pdf)    Illustrations (pdf)

Question and Answer session: Audio Podcast   Transcript (pdf)   Illustrations (pdf)

  Radiation for Prevention and Management of Brain Metastases in Lung Cancer

With Dr. Minesh Mehta, Professor of Radiation Oncology at Northwestern University.
Audio and transcripts:

Audio Podcast     Transcript (pdf)   Illustrations (pdf)

Acquired Resistance to EGFR Inhibitors (Pt 1)

Dr. Lecia Sequist, medical oncologist and lung cancer expert from Harvard Medical School and Massachusetts General Hospital (MGH), recently joined us for a live webinar by LUNGevity Foundation and GRACE.

Audio Podcast     Video     Transcript (pdf)    Presentation (pdf)

Acquired Resistance to EGFR Inhibitors (Pt 2)

At the time of her Dr. Sequist's first presentation, she was unable to discuss some very new work that was about to be published on their experience at MGH in repeating biopsies on patients over the course of their ongoing treatment, and the interesting and sometimes treatment-changing results they found.

This second podcast includes her presentation on this very timely information that was, surprising to many in the lung cancer community, as well as to the investigators themselves. The presentation is in video and audio podcast forms, along with the associated transcript and figures.

Audio PodcastTranscript (pdf)     Presentation (pdf)


Challenging Cases in Lung Cancer Series

This is a series of podcasts developed in partnership with GRACE, in which Dr. Jack West presents the same challenging cases in lung cancer management to a series of experts to learn the range of views offered by them, then the multiple thoughtful comments by all of them discussing the same single featured case for each podcast. 

The first case is a discussion of how they would approach a patient who has a small primary tumor that also has a separate microscopic satellite lesion nearby.  Here are the links to the audio and video versions of the podcast (there isn’t a lot of video to see), along with the transcript:

Audio Podcast     Transcript (pdf)

This case is of a woman with a tumor that is in the range that is smaller than that for which we would routinely recommend post-operative (adjuvant) chemotherapy to reduce the risk of recurrence, but the tumor has some higher risk features that lead her, and might lead us, to be more inclined to recommend it despite the smaller size of the tumor (which is still within a pretty debatable range).

Audio Podcast     Transcript (pdf)

This discussion is on the common but vexing scenario of a patient with mediastinal node-positive (stage IIIA N2) NSCLC.  This is among the most controversial clinical settings in lung cancer, as illustrated by the wide range of answers of how the experts in this program would manage the same patient.

Audio Podcast    Transcript (pdf)

This particular case is one we struggle with all the time. Once someone with unresectable stage III NSCLC has completed initial chemo/radiation, typically over an approximately seven week period, should we recommend any additional treatment after that.

Audio Podcast     Transcript (pdf)   Illustrations (pdf)

 

The information provided in the Ask the Experts section is provided by GRACE.

The information provided by GRACE and LUNGevity Foundation is for informational purposes only. The faculty of GRACE and the staff of LUNGevity are not providing medical advice, diagnosis or treatment and cannot replace the medical advice of your doctor or health care provider. Any personal information you supply in these pages will be shared by LUNGevity Foundation and GRACE and is subject to the conditions and policies of both organizations. Click here for GRACE's full terms and conditions. Click here for LUNGevity's privacy policy.